i work in the oil tanker industry and these vessels have huge back up batteries in case engine doesn't star..
nothing more dangerous than an oil tanker with over 1 million bbls of oil not being able to sail on its on or stop pumping ..etc...
Swiss . i don't know how you think this is positive.. Garo hasn't said a word about it.. and it seems to have gone nowhere.... so its approved in Russia ..but never sold a single dose?
I thought it was an odd moment when no questions where asked as well.. .. either i have completely over estimated the value of this stock or quite the opposite . .that people may not get it at all .. and until the moment they see the remissions .. and get better PR they won't get it .. ..
agree Biopearl... what the hold up with the MDS data and the publishing of the papers? hopefully we will hear soon
he is doing what almost all bio tech ceo are doing .. presenting at this big conference......hopefully he has more information .. better slides.. im suprised nothing more from Tefferi ..as far as papers or anything since he is taking on IMET with geron
i have been here about as long as you .. im starting to believe you im a little slow obviously
Thanks reply.. that is significant then.............. and i misspelled on my original post .. i meant to say we had mixed results not missed ..
Please what is the date of this study? as mentioned by others .. we had missed results on the solid tumors and stopped.. if this is new then could be significant news..
Ive seen drugs fast tracked for less impressive results .. we are talking Complete Remission in a few patients .. this is unheard of . Think Scarlett sold us short .. and still is ... accumulation at these levels is attractive but if insiders would buy some stock then it may show some confidence from their own pockets not just bonus shares... .. this has always made me cautious .. are they scared if they buy their cure that they will get sued for insider buying? something still smells
hopefully sign of things to come.. for GERNAfter Gilead Sciences won FDA approval for its cancer drug Zydelig last summer, some investors worried that sales of Johnson & Johnson (NYSE: JNJ ) and Pharmacyclics' (NASDAQ: PCYC ) Imbruvica, which is approved to treat the same indications as Zydelig, would falter. However, those worries appear overblown given that at the JP Morgan Healthcare Conference today Pharmacyclics issued rosy Imbruvica sales estimates for 2015 and forward looking guidance that suggests that Imbruvica is on track to be a top seller for J&J and Pharmacyclics for years to come.
First, a bit of background
Imbruvica's efficacy in early stage clinical trials prompted J&J to agree to pay Pharmacyclics $975 million in milestones, including $150 million upfront, as well as split profits on eventual sales, to co-develop the drug in 2011.
lots of nay sayers today.. this stock now has a lot of important deals done .. shorts nightmare.. and a few surprises left .. I think its 15 bucks by year end . We have Malaria and Shingles vaccine news and prophage.. plus many undisclosed qs21 programs .. and Herpv could be a huge surprise if booster does well..